SOURCE: ViaDerma, Inc.

November 14, 2016 17:59 ET

ViaDerma, Inc. Enters the (MMJ) or Medical Marijuana industry with a Patent Pending CBD Delivery System as California Votes for Expanded Uses of Cannabis

The Treatment Success of ViaDerma's Proprietary Delivery System for Several Diseases by the Efficient and Effective Transdermal Delivery of CBD's & THC to the Localized Treatment Area & into the Blood Stream

LOS ANGELES, CA--(Marketwired - November 14, 2016) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today the Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream. The Patent application using the combination of CBD's and THC with the delivery system was filed in 2014. The Patent Pending transdermal system can deliver medications and nutrients into the body through the skin. For example, a person with a migraine headache can place the CBD and THC combined with the delivery compound and apply to the neck with immediate absorption into the bloodstream through the corroded artery. ViaDerma, Inc. is also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido.

On November 8th, medical and recreational marijuana was passed in several states that voted on medical marijuana provisions, in what is turning out to be, the biggest electoral victory for marijuana reform since 2012. The use of CBD's is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.

ViaDerma also has Viabecline, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.' Without the introduction of novel antibiotic treatments, infections can spread and sometimes become life threatening.

Market for the following Drugs:

Topical antibiotics- $6 billion/year
Toenail antifungal drugs- $3 billion/year
Diabetic amputations- $3 billion/year
Global acne- $2.8 million in 2009, estimates of $3.02 billion by 2016
Psoriasis- $2.4 billion in 2010, estimates of over $7.3 billion by 2015
Eczema- $2.5 billion in 2014

ViaDerma sees the use of CBD's along with our Proprietary transdermal delivery system for the treatment and continuing studies look very promising and demonstrate efficacy in terms of treating several unrelated diseases. "We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community," said Dr. Christopher Otiko, ViaDerma's founder and CEO.

About ViaDerma, Inc.
ViaDerma, Inc. (OTC PINK: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, TetraStem™, uses an innovative transdermal delivery method that allows for application of active ingredients in a topical form. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. For more information, please visit: www.viadermalicensing.com.

Forward-Looking Statements
Forward-Looking Statements certain statements in this release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified using words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "intend," and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including but not limited to the Company's ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management and human resources and infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company's control; and (iv) other risk factors. We assume no obligation to update the information contained in this news release.

Contact Information